Zimmer Biomet exec sells 5,691 shares at $92.95

A senior Zimmer Biomet officer sold 5,691 common shares and reported no remaining direct holdings after the transaction.

Rhea-AI Filing Summary

ZIMMER BIOMET HOLDINGS, INC. (ZBH) officer Kevin R. Thornal, Group President–Global Business, reported selling 5,691 shares of common stock on September 11, 2026 in an open market or private transaction at $92.95 per share. Following this transaction, he reported holding no shares directly, and no Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Net Seller: 5,691 shares

Net Sell 1 txn

Insider Thornal Kevin R

Role Grp Pres-Global Business

Sold 5,691 shs ($529K)

Type	Security	Shares	Price	Value
Sale	Common Stock	5,691	$92.95	$529K

Holdings After Transaction: Common Stock — 0 shares (Direct)

Key Figures

Shares sold: 5,691 shares Sale price per share: $92.95 per share Direct holdings after transaction: 0 shares +1 more

4 metrics

Shares sold 5,691 shares Common stock sale reported for September 11, 2026

Sale price per share $92.95 per share Price for the 5,691 common shares sold on September 11, 2026

Direct holdings after transaction 0 shares Total common stock directly held by Kevin R. Thornal after the sale

Net shares sold 5,691 shares Net sell direction across all transactions in this Form 4

Key Terms

Common Stock, open market or private transaction, Rule 10b5-1 plan

3 terms

Common Stock financial

"reported selling 5,691 shares of common stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

open market or private transaction financial

"Sale in open market or private transaction"

Rule 10b5-1 plan regulatory

"no Rule 10b5-1 trading plan is reported"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ZIMMER BIOMET (ZBH) report for Kevin R. Thornal?

Kevin R. Thornal reported a sale of 5,691 shares of Zimmer Biomet common stock on September 11, 2026 in an open market or private transaction at $92.95 per share.

How many ZBH shares does Kevin R. Thornal hold after this Form 4 transaction?

After the reported transaction, Kevin R. Thornal is shown as holding 0 shares of Zimmer Biomet common stock directly.

What was the price for the Zimmer Biomet (ZBH) shares sold by Kevin R. Thornal?

The reported sale price was $92.95 per share for the 5,691 shares of Zimmer Biomet common stock sold on September 11, 2026.

Was Kevin R. Thornal’s ZBH share sale under a Rule 10b5-1 trading plan?

No. The filing indicates no Rule 10b5-1 plan is reported, meaning the document-level trading plan checkbox is not marked as an affirmed Rule 10b5-1 plan.

What is Kevin R. Thornal’s role at ZIMMER BIOMET HOLDINGS, INC. (ZBH)?

Kevin R. Thornal is reported as an officer of Zimmer Biomet with the title Group President–Global Business.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/15/2026 - 04:24 PM Accepted by SEC EDGAR 09/15/2026 - 04:24 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Thornal Kevin R

(Last) (First) (Middle)

345 E. MAIN STREET

(Street)

WARSAW INDIANA 46580

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ZIMMER BIOMET HOLDINGS, INC. [ ZBH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Grp Pres-Global Business

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/11/2026		S		5,691	D	$92.95	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Matthew R. St. Louis, Attorney-in-Fact for Kevin Thornal (power of attorney previously filed)	09/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)